Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof

Abstract

The present invention relates to the compound according to Formula I, and to its use in medicine, in particular in the treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons. In particular, the compound inhibits JAK a family of tyrosine kinases, and more particularly JAK1. The present invention also provides pharmaceutical compositions comprising the compound, methods for the prophylaxis and/or treatment of diseases involving inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons by administering the compound.

1 . A method for the treatment of a mammal susceptible to or afflicted with inflammatory bowel disorder, which method comprises administering a therapeutically effective amount of a compound according to Formula I: 
       
         
           
           
               
               
           
         
       
     
     
         2 . The method according to  claim 1 , wherein the said compound is administered in combination with one or more additional therapeutic agents, wherein said additional therapeutic agent is an inflammatory bowel disorder treating agent. 
     
     
         3 . (canceled) 
     
     
         4 . The method according to  claim 2 , wherein the additional therapeutic agent is according to Formula II: 
       
         
           
           
               
               
           
         
       
     
     
         5 . The method according to  claim 4 , wherein the ratio of Formula I/Formula II is from 1/5 to 1/20. 
     
     
         6 . The method according to  claim 4 , wherein the ratio of Formula I/Formula II is from 1/5 to 1/10. 
     
     
         7 . The method according to  claim 1 , wherein the mammal is a human. 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . (canceled) 
     
     
         18 . (canceled) 
     
     
         19 . (canceled) 
     
     
         20 . (canceled) 
     
     
         21 . (canceled) 
     
     
         22 . (canceled) 
     
     
         23 . (canceled) 
     
     
         24 . The method according to  claim 1 , wherein the inflammatory bowel disorder is colitis. 
     
     
         25 . The method according to  claim 1 , wherein the inflammatory bowel disorder is Crohn's disease. 
     
     
         26 . The method according to  claim 2 , wherein the inflammatory bowel disorder is colitis. 
     
     
         27 . The method according to  claim 2 , wherein the inflammatory bowel disorder is Crohn's disease.